DelveInsight's, "Advanced Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in
Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report *
Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking
Advanced Hepatocellular Carcinoma Emerging Drugs
Tivozanib : AVEO Oncology
FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
Nofazinlimab:
CS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.
ECT 204: Eureka Therapeutics
ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.
Sintilimab:
Sintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT® (sintilimab injection) in
Learn more about Advanced Hepatocellular Carcinoma Drugs Opportunities in our groundbreaking
Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration *Intra-articular *Intraocular *Intrathecal *Intravenous *Ophthalmic *Oral *Parenteral *Subcutaneous *Topical *Transdermal
Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as *Oligonucleotide *Peptide *Small molecule
Discover the latest advancements in Advanced Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Advanced Hepatocellular Carcinoma Pipeline Report *Coverage- Global *
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Hepatocellular Carcinoma Pipeline on our website @ Advanced Hepatocellular Carcinoma Emerging Drugs and Companies
Table of Content *Introduction *Executive Summary *Advanced Hepatocellular Carcinoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Advanced Hepatocellular Carcinoma- DelveInsight's Analytical Perspective *Late Stage Products (Pre-Registration) *Drug name: Company Name *Drug profiles in the detailed report..... *Last Stage Products (Phase III) *Nofazinlimab:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source